MARKET

ICCC

ICCC

ImmuCell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.980
-0.730
-12.78%
Closed 16:00 07/31 EDT
OPEN
5.71
PREV CLOSE
5.71
HIGH
5.71
LOW
4.980
VOLUME
100.97K
TURNOVER
--
52 WEEK HIGH
8.13
52 WEEK LOW
3.700
MARKET CAP
35.92M
P/E (TTM)
-22.9811
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ICCC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.

EPS

ICCC News

More
ImmuCell sees Q2 product sales as high as $3M
Seeking Alpha - Article · 07/07 13:45
ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020
GlobeNewswire · 07/07 13:00
ImmuCell Sees Prelim. Q2 Total Product Sales $3M, Up 9% YoY
PORTLAND, Maine, July 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets
Benzinga · 07/07 12:19
ImmuCell Receives $500,000 Loan from the Maine Technology
GlobeNewswire · 06/16 13:00
Edited Transcript of ICCC earnings conference call or presentation 14-May-20 1:00pm GMT
Q1 2020 ImmuCell Corp Earnings Call
Thomson Reuters StreetEvents · 05/18 15:48
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/14 19:14
ImmuCell Corporation to Present at Lytham Partners Virtual Investor Conference
ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced it will participate in a
PR Newswire · 05/14 17:35
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
GlobeNewswire · 05/14 13:42

Industry

Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-1.15%

Hot Stocks

Symbol
Price
%Change

About ICCC

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
More

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.